Introduction {#sec1-1}
============

Gestational diabetes mellitus (GDM) is a common medical complication of pregnancy that can adversely affect the health of both the mother (hypertension, increased chances of cesarean section, hydramnios, preeclampsia, etc.) and the fetus (restriction of fetal growth, macrosomia, hyperbilirubinemia, hypoglycemia, and shoulder dystocia).\[[@ref1]-[@ref3]\] GDM is characterized by hyperglycemia that is diagnosed for the 1^st^ time in pregnancy (in the absence of any pre-existing Type-1 or type-2 diabetes).\[[@ref3],[@ref4]\] The hyperglycemic situation in GDM is temporary and generally normalizes once the pregnancy is over.\[[@ref5],[@ref6]\]

Self-monitoring of blood glucose (SMBG) is often recommended as a part of GDM management.\[[@ref7]-[@ref9]\] SMBG is performed by putting a drop of blood (obtained by puncturing the skin of the tip of the finger using a needle) on a strip which is then read using a glucose reading meter.\[[@ref10]\]

Despite the emphasis on SMBG-testing as a treatment component of GDM,\[[@ref7]-[@ref9]\] much is not known about its barriers and compliance among the GDM patients. Most studies related to the barriers and compliance of SMBG-testing are primarily based on Type 1 and Type 2 diabetes patients.\[[@ref10]-[@ref14]\]

Therefore, to appreciate the existing evidence (and its rigor) of the barriers of SMBG and the factors that determine the compliance to SMBG in GDM patients, this systemic review was done.

In this study, the terms adherence and compliance are used interchangeably due to their similar type of meaning.\[[@ref15]-[@ref17]\]

Methods {#sec1-2}
=======

This systemic review does not have a pre-published protocol. This study made every possible attempt to adhere strictly to the PRISMA reporting system to report its findings.\[[@ref18]\]

Eligibility criteria: Inclusion criteria: (1) Studies that assessed the barriers to SMBG-testing and/or the factors attributing to the compliance of SMBG-testing in GDM patients (2) studies that were conducted and published between March 2010 and June 2018, (3) studies of following types were included in the study -- qualitative studies, observational studies, experimental studies, and systemic review with or without meta-analysis (that include studies conducted and published in March 2010 or later), and (4) articles that are available in English language only.

Exclusion criteria {#sec2-1}
------------------

\(1\) Studies that included Type-1 diabetes and/or Type-2 diabetes patients along with GDM patients as their study population were excluded from the study.

Following databases were searched for the purpose of this study -- PubMed, EMBASE, SCOPUS, PsycINFO, PROQUEST, and CINAHL. The search was restricted to all articles published between March 2010 and June 2018. The last date of the search was on June 30, 2018. None of the authors of the studies included in this paper were contacted.

Following search terms were used for the database search -- ("adherence" odds ratio \[OR\] "perception" OR "barrier" OR "compliance OR "behavior") AND ("SMBG" OR "self-monitoring") AND ("GDM" OR "gestational diabetes").

Besides, the above-mentioned database search hand search was done in the bibliography of the articles included in this article. An additional search (using the search terms mentioned above) was also done in the internet search engine -- "Google" (<https://www.google.com/>). Furthermore, the search was also extended to the PROSPERO website (<https://www.crd.york.ac.uk/prospero/>)\[[@ref19]\] to identify any currently ongoing protocols that might also be reviewing similar outcomes like this study.

The rationale for choosing the papers published after March 2010 is discussed here. The diagnosis of GDM had been chaotic globally due to the use of different diagnostic criteria (to diagnose GDM) in different countries.\[[@ref5],[@ref20]\] In March 2010, The International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria for the diagnosis of GDM became available\[[@ref20],[@ref21]\] which was endorsed by the World Health Organization and various countries across the globe.\[[@ref20]-[@ref22]\] Therefore, in view of this wide consensus for the IADPSG (2010) guideline for GDM diagnosis,\[[@ref20]-[@ref22]\] the studies conducted and published in March 2010 and onward were screened for inclusion in this paper.

Following procedure was used to screen and select the studies for reviewing. At first, the abstract of all the articles found during the search was read. Next, the papers that appeared to meet the eligibility criteria of this study (through abstract review) were selected for a full-paper review. In addition, full papers were reviewed when an inclusion or exclusion decision was not possible by reading the abstract alone.

During the full-text reading (of the sorted papers), all articles that matched this study's eligibility criteria were included in this review (for data extraction and analysis). The entire work for this paper (from the planning of this study to database search, data extraction, data analysis, and the write-up) was conducted by the author independently (single author).

Data collected from each of the studies primarily included -- the surname of first author, the year of publication, the country where the study was conducted, the study design, the study population, the barriers of SMBG, the factors determining the compliance to SMBG, and the diagnostic criteria used to diagnose GDM.

Following study design related information were extracted from each study -- the study type, interventions (SMBG-related) if any, frequency, and duration of such intervention, if there was any comparison or control group, the assessed outcome, the data collection method, information about the conflict of interest, and funding related information. The study population relevant information that were extracted was -- the sample description, the sample size, any dropouts, the gestational age of the study participants, the age range of the study participants, the mean age of the study sample, the sampling procedure, and the inclusion and exclusion criteria of the study (in relevance to this study's objectives).

Risk of bias of the individual studies was assessed using the 4^th^ Edition of Joanna Briggs Institute (JBI) Reviewer's Manual.\[[@ref23]\]

Results obtained from the studies reviewed in this paper were analyzed qualitatively, as a meta-analysis was not possible (due to lack of comparable data).\[[@ref18]\] Any bias in the reported outcome of the individual papers (included in this systemic review) was assessed by matching the aims' of these studies against their reported results.\[[@ref18]\]

All illustrations (tables and diagrams) are placed at the end of this paper (after the references).

Results {#sec1-3}
-------

In total, 42 papers were identified using the above-described literature search. There were 17 duplicates which were manually screened and excluded. After excluding the duplicates, 25 studies were screened by reading the abstracts (against the eligibility criteria of this study) and 12 studies were selected for full paper review. Finally, six papers were rejected, and the remaining six papers\[[@ref24]-[@ref29]\] were accepted for this review \[[Diagram 1](#F1){ref-type="fig"}\]. Inclusion and exclusion of the studies were strictly based on the eligibility criteria mentioned above.

![PRISMA 2009 flow diagram\[[@ref18]\]](IJHS-13-44-g001){#F1}

Data extracted from the selected studies in this review have been depicted in a summary table \[[Table 1](#T1){ref-type="table"}\]. Out of the six papers, four were quasi-experimental studies\[[@ref26]-[@ref29]\] and two were qualitative studies.\[[@ref24],[@ref25]\]

###### 

Summary table

![](IJHS-13-44-g002)

The risk of bias of the selected studies was assessed using the respective JBI tools available for these types of studies.\[[@ref30],[@ref31]\] The critical appraisal depicted that the qualitative studies \[[Table 2](#T2){ref-type="table"}\] were of good quality.\[[@ref24],[@ref25]\] On the other hand, the critical appraisal of the quasi-experimental studies\[[@ref26]-[@ref29]\] revealed that only one study\[[@ref29]\] had a relatively good study design, methodology, and analysis \[[Table 3](#T3){ref-type="table"}\].\[[@ref26]-[@ref28]\] It is the only quasi-experimental study\[[@ref29]\] that compared its finding with a control group. None of the quasi-experimental studies\[[@ref26]-[@ref29]\] did any pre- and post-intervention comparison of their findings.

###### 

Qualitative studies\[[@ref31]\]

![](IJHS-13-44-g003)

###### 

Quasi-experimental studies\[[@ref30]\]

![](IJHS-13-44-g004)

The qualitative studies reviewed in this study identified some of the potential barriers of SMBG in GDM patients. The study conducted in China (*n* = 17) identified the poor understanding of SMBG-testing among GDM patients and lack of SMBG-recommendation by the health-care providers as the barriers to perform SMBG,\[[@ref25]\] whereas the study conducted in Thailand (*n* = 30) found fear and worry about performing an SMBG-test as a barrier.\[[@ref24]\]

The results of the quasi-experimental studies reveal the following finding. Cosson *et al*.\[[@ref26]\] (*n* = 94) reported that poor compliance to SMBG (*n* = 35, 38%) was independently associated with family history of Type-2 diabetes in first-degree relatives (OR = 0.38, 95% confidence interval \[CI\] 0.15--0.98), *P* = 0.044).\[[@ref26]\] The study further identified that French ethnicity and having medical insurance (for the impoverished patients) were also associated with non-compliance to SMBG in GDM patients (however, the OR and CI were not reported for these findings).\[[@ref26]\] The study by Peleg *et al*.\[[@ref29]\] unveiled that compliance to SMBG-testing improved by the use of smartphone-based reminders in the participants of the intervention group (t-statistics 2.166, *P* = 0.0312).\[[@ref29]\]

The remaining quasi-experimental studies measured the compliance to SMBG testing among GDM patients in percentages.\[[@ref27],[@ref28]\] The study by Mackillop *et al*. (*n*=104) found that the use of a smartphone to record blood glucose readings resulted in good SMBG-testing compliance.\[[@ref27]\] Almost 85% of the participants (46 out of 54) of this study did the test as per the research team's pre-determined optimum SMBG frequency,\[[@ref27]\] whereas the Sousa *et al*. study\[[@ref28]\] (*n* = 135) reported 97.5% of the study participants (119 of 122) to be compliant to the SMBG recommendations. The study also found that about 17% of the GDM patients (21/122) perceived the lancet of the needle (to obtain blood for SMBG) and the time of conducting the SMBG-test as the barriers to SMBG.\[[@ref28]\]

A forest plot or meta-analysis was not considered as a part of this systemic review, as the studies included for this review were not comparable (being a combination of qualitative and quantitative) and the quantitative ones\[[@ref26]-[@ref29]\] were also quite a few in number.\[[@ref18]\]

Overall, the results obtained from the reviewed studies lacked rigor and external validity. The strength and weaknesses of these studies are enumerated in the successive paragraphs.

Study design and study methodology-wise out of the three quasi-experimental studies that reported good compliance to SMBG-testing,\[[@ref27]-[@ref29]\] the evidence is stronger only for the Peleg *et al*. study\[[@ref29]\] since it used a control group to compare its finding (along with an appropriate statistical test). However, the methodology of calculating the compliance to the SMBG-testing was different among these three studies and hence not comparable.\[[@ref27]-[@ref29]\]

Both of the qualitative studies\[[@ref24],[@ref25]\] and two of the quasi-experimental studies\[[@ref26],[@ref28]\] addressed the barriers to SMBG testing (mentioned above). However, the evidence is perhaps weakened due to the following reasons. Several components that are not clear in the qualitative studies are -- the influence of researchers on the study population,\[[@ref24],[@ref25]\] how the cultural or theoretical beliefs of the researchers were related to their study,\[[@ref24],[@ref25]\] the language in which the interviews were conducted,\[[@ref24]\] and the quality and validity assessment of the English language translations of the verbatim transcripts.\[[@ref25]\] Whereas the hazy areas of the quasi-experimental studies\[[@ref26],[@ref28]\] that dealt with SMBG-barriers were -- absence of a control group or a pre-intervention finding to compare with the post-intervention findings,\[[@ref26],[@ref28]\] the measurement methods of barriers to SMBG-testing in GDM patients were not consistent among the two studies,\[[@ref26],[@ref28]\] and lack of validity-related information of the questionnaire used in one of these studies (to understand the barriers of SMBG in GDM patients).\[[@ref28]\]

None of the studies except Cosson *et al*.\[[@ref26]\] utilized any diagnostic criteria to define GDM in their study population.

Overall, the studies\[[@ref24]-[@ref29]\] measured or analyzed what they intended to measure or analyze.

The additional search in the PROSPERO website (<https://www.crd.york.ac.uk/prospero/>)\[[@ref19]\] (as of June 30, 2018) identified a Cochrane protocol that is in "review ongoing" status.\[[@ref32]\] This study is currently assessing adherence to SMBG-testing in GDM patients as a secondary outcome in randomized control trials, quasi-randomized control trails, and cluster-randomized control trials.\[[@ref32]\] However, if the barriers to SMBG-testing among GDM patients are going to be reviewed or not in this Cochrane review is not clear.\[[@ref32]\]

None of the hand searched literature matched the eligibility criteria of this review, hence not included.

Discussion {#sec1-4}
==========

The literature review conducted in this study identified a severe shortage of studies that have tried to understand the barriers and compliance to SMBG in GDM patients. There are several shortfalls of the existing literature which are discoursed here. Overall, the study population-related description such as the previous history of GDM, the gestational age at which the study participants were recruited, the obstetric history (the gravida and parity), and age range of participants was not available throughout these studies consistently. Study population characteristics such as previous history of GDM, gravida, and parity-related information were available in only one of the studies done by Youngwanichsetha and Phumdoung.\[[@ref24]\] Only two studies (the qualitative ones) mentioned the gestational age of their study population.\[[@ref24],[@ref25]\] The age range of the study participants was available for only one study,\[[@ref25]\] and only three out of the six studies provided a mean age.\[[@ref24],[@ref26],[@ref29]\] Exclusion criteria were not clearly stated in most studies.\[[@ref24]-[@ref27],[@ref29]\] This lack of basic study population defining features made comparison across these studies difficult.

Study population-related confusion was also witnessed in one study, between its two phases.\[[@ref27]\] In the first phase, a pilot testing of the role of mobile technology in SMBG compliance was done.\[[@ref27]\] Based on the feedback from the participants of the pilot test necessary changes was made to the mobile technology and was re-tested in GDM patients for SMBG compliance in the second phase.\[[@ref27]\] The reporting of the result was unclear because it reported compliance (85%, i.e. 46 out of 54) based on all participants of both phases of the study although the mobile technology in the second phase (upgraded) was not same as the first phase.\[[@ref27]\] The comparison between the two phases was complicated further as the info about what medications the participants were on while in the study was only available for those enrolled in the second phase (who were not treated with insulin or metformin).\[[@ref27]\] Nevertheless, a separate group wise frequencies for the compliance was available in the study.\[[@ref27]\]

Regarding the quasi-experimental studies,\[[@ref26],[@ref28],[@ref29]\] sampling-related information such as sampling method and sample size calculation was grossly unavailable. The study by Mackillop *et al*.\[[@ref27]\] was an exception in this regard. It recruited all women who attended the diabetes-maternity clinic (in the second phase).\[[@ref27]\] However, the calculation of power or factors that might have strengthened or compromised the statistical power was not available for any of these non-randomized experimental studies.\[[@ref24],[@ref26]-[@ref29]\] Lack of power related information made it difficult to comment on the strength of the evidence produced from the studies.

Then, regarding the confounders, none of the four quasi-experimental studies,\[[@ref26]-[@ref29]\] except one,\[[@ref26]\] considered for adjusting the confounders. It was also not clear if any other methods such as randomization or matching were used by the quasi-experimental studies\[[@ref26]-[@ref29]\] to decrease any bias due to confounding. The effects of an intervention are generally at risk of confounding and efforts should be made to identify and control them to avoid undue bias.\[[@ref33]\] Confounding can be controlled by stratification, adjusting, matching, randomization, etc.\[[@ref33]\]

Next, quasi-experimental studies are considered to be of better rigor and quality when they include a pre- and post-intervention comparison and/or a comparison with a control group, rather than without such comparisons.\[[@ref34]\] None of the quasi-experimental studies\[[@ref26]-[@ref29]\] included in this review mentioned a pre- and post-comparison of their findings. Out of the four quasi-experimental studies,\[[@ref26]-[@ref29]\] only one study\[[@ref29]\] compared its findings with a control group. Therefore, in regard to comparability of the results, the studies are relatively weak.

Comparability of the four quasi-experimental studies\[[@ref26]-[@ref29]\] weakened further since the method of assessing compliance among these studies\[[@ref26]-[@ref29]\] was not consistent. Cosson *et al*.\[[@ref26]\] considered participants to be compliant with SMBG when at least 80% of the total (pre- and post-prandial) SMBG tests were done,\[[@ref26]\] whereas, Peleg *et al*.\[[@ref29]\] measured the compliance by dividing the recommended number of SMBG over a time period by the number of SMBG tests done during that period.\[[@ref29]\] On the other hand, the study by Mackillop *et al*.\[[@ref27]\] ensured compliance when 18 SMBG tests were done per week. In Sousa *et al*. study,\[[@ref28]\] the compliance determination method was not clear.\[[@ref28]\]

The causes of non-compliance to SMBG among the GDM patients were studied in the Cosson *et al*. study.\[[@ref26]\] However, only for one cause of non-compliance (the family history of Type 2 diabetes in first-degree relatives) (OR = 0.38, 95% CI 0.15--0.98, *P* = 0.044) an OR and CI were available, for assessing the strength of association.\[[@ref26]\] Other causes of non-compliance identified by this study (not-belonging to French ethnicity (*n* = 28, *P* = 0.048) and having medical insurance dedicated for the impoverished (*n* = 9, 26%, *P* = 0.033)\[[@ref26]\] were difficult to interpret because the results were reported in statistical significance (p-value) only (for the respective variables) with no clear mention about the strength of association (like the OR) and the precision of such association (e.g., the 95% CI).\[[@ref26],[@ref35]\]

None of the quasi-experimental studies\[[@ref26]-[@ref29]\] have a clear mention of the raters and inter- and intra-rater reliability about the cause and effect relationship derived statistically.\[[@ref30]\]

Although the qualitative studies\[[@ref24],[@ref25]\] were of good quality (fulfilling most of the critical appraisal criteria \[[Table 2](#T2){ref-type="table"}\]), certain issues question the overall rigor of these studies. Only one of the two qualitative studies clearly mentioned its sampling method (purposive).\[[@ref25]\] The interview transcripts in Ge *et al*.\[[@ref25]\] study were translated from Mandarin Chinese language to the English language; however, information about the translation quality and its validity is not clearly depicted.\[[@ref25]\] In the other qualitative study, interviewers were in contact with the participants for a substantial duration -- it is not clear from the study if such engagement anyhow affected (biased) the participant responses and if anything was done to address it.\[[@ref24]\]

Information regarding the GDM diagnostic criteria used to identify GDM patients was available only for one study.\[[@ref26]\] It used the IADPSG criteria\[[@ref21]\] to diagnose GDM.\[[@ref26]\]

Conflict of interest and funding related declaration were available for all studies except the study by Sousa *et al*.\[[@ref28]\] None of the authors of the studies\[[@ref24]-[@ref29]\] incorporated in this review were contacted.

Limitations of this study {#sec2-2}
-------------------------

This study was based on a literature search of a relatively short time span, less than a decade (from March 2010 to June 2018), which might have compromised the scope of reviewing a larger number of studies.

Conclusion {#sec1-5}
==========

To understand the barriers to SMBG and the factors that determine the compliance of SMBG among GDM patients, this systemic review was conducted. This review included relevant articles published between March 2010 and June 2018. There were few studies (six only) that met the eligibility criteria of this review. The studies reviewed in this paper reported the following barriers of SMBG in GDM patients -- lack of SMBG-testing recommendation by health-care providers, poor concept, fear, and anxiety about SMBG-testing, and family history of Type 2 diabetes.\[[@ref24]-[@ref26],[@ref28]\] The compliance to SMBG-testing in GDM patients improved with the use of education (SMBG related) and technology (smartphone and mobile-based).\[[@ref27]-[@ref29]\] However, these results are not comparable across the studies. Moreover, the results are not generalizable due to the respective weaknesses of the studies discussed in this paper. Therefore, based on this review, the current evidence regarding SMBG related barriers and compliance in GDM patients are labeled as weak and inadequate (for an external validity). Henceforth, further research is required on this topic.
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